Innventure, Inc. (INV)
NASDAQ: INV · Real-Time Price · USD
4.500
-0.120 (-2.60%)
At close: Aug 1, 2025, 4:00 PM
4.460
-0.040 (-0.89%)
After-hours: Aug 1, 2025, 4:20 PM EDT
Oncternal Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Oncternal Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $14, which forecasts a 211.11% increase in the stock price over the next year. The lowest target is $12 and the highest is $16.
Price Target: $14.00 (+211.11%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 12, 2025.
Analyst Ratings
The average analyst rating for Oncternal Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|
| Strong Buy | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Northland Capital Markets | Northland Capital Markets | Buy Initiates $12 | Buy | Initiates | $12 | +166.67% | Mar 12, 2025 |
| Roth MKM | Roth MKM | Strong Buy Initiates $16 | Strong Buy | Initiates | $16 | +255.56% | Jan 23, 2025 |
Financial Forecast
Revenue This Year
13.98M
from 1.22M
Increased by 1,045.66%
Revenue Next Year
47.59M
from 13.98M
Increased by 240.46%
EPS This Year
-3.40
from -1.41
EPS Next Year
-0.36
from -3.40
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 32.8M | 105.6M |
| Avg | 14.0M | 47.6M |
| Low | 2.2M | 16.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | 2,589.6% | 655.7% |
| Avg | 1,045.7% | 240.5% |
| Low | 76.7% | 18.5% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -3.34 | -0.05 |
| Avg | -3.40 | -0.36 |
| Low | -3.49 | -0.66 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.